300 related articles for article (PubMed ID: 10673535)
1. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
Baker SD; Diasio RB; O'Reilly S; Lucas VS; Khor SP; Sartorius SE; Donehower RC; Grochow LB; Spector T; Hohneker JA; Rowinsky EK
J Clin Oncol; 2000 Feb; 18(4):915-26. PubMed ID: 10673535
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
Grem JL; Harold N; Shapiro J; Bi DQ; Quinn MG; Zentko S; Keith B; Hamilton JM; Monahan BP; Donavan S; Grollman F; Morrison G; Takimoto CH
J Clin Oncol; 2000 Dec; 18(23):3952-63. PubMed ID: 11099325
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
Ochoa L; Hurwitz HI; Wilding G; Cohen D; Thomas JP; Schwartz G; Monroe P; Petros WP; Ertel VP; Hsieh A; Hoffman C; Drengler R; Magnum S; Rowinsky EK
Ann Oncol; 2000 Oct; 11(10):1313-22. PubMed ID: 11106122
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
[TBL] [Abstract][Full Text] [Related]
7. Clinical development of eniluracil: current status.
Hohneker JA
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):52-6. PubMed ID: 9830627
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of fluorinated pyrimidines: eniluracil.
Baker SD
Invest New Drugs; 2000 Nov; 18(4):373-81. PubMed ID: 11081573
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
Meropol NJ; Niedzwiecki D; Hollis D; Schilsky RL; Mayer RJ;
Cancer; 2001 Apr; 91(7):1256-63. PubMed ID: 11283924
[TBL] [Abstract][Full Text] [Related]
10. Oral eniluracil/5-FU for advanced colon and breast carcinomas.
Benson AB
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):57-63; discussion 64. PubMed ID: 11219979
[TBL] [Abstract][Full Text] [Related]
11. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
O'Donnell A; Punt CJ; Judson I; Van Maanen L; Suttle AB; Ertel P; Beale P
Cancer Chemother Pharmacol; 2003 Jan; 51(1):58-66. PubMed ID: 12497207
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
Baker SD; Khor SP; Adjei AA; Doucette M; Spector T; Donehower RC; Grochow LB; Sartorius SE; Noe DA; Hohneker JA; Rowinsky EK
J Clin Oncol; 1996 Dec; 14(12):3085-96. PubMed ID: 8955653
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer.
Rivera E; Sutton L; Colwell B; Graham M; Frye D; Somerville M; Conklin HS; McGuirt C; Levin J; Hortobagyi GN
J Clin Oncol; 2002 Feb; 20(4):987-93. PubMed ID: 11844821
[TBL] [Abstract][Full Text] [Related]
14. A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
Czito BG; Hong TJ; Cohen DP; Tyler DS; Lee CG; Anscher MS; Ludwig KA; Seigler HF; Mantyh C; Morse MA; Lockhart AC; Petros WP; Honeycutt W; Spector NL; Ertel PJ; Mangum SG; Hurwitz HI
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):779-85. PubMed ID: 14967434
[TBL] [Abstract][Full Text] [Related]
15. Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study.
Smith IE; Johnston SR; O'Brien ME; Hickish TF; de Boer RH; Norton A; Cirkel DT; Barton CM
J Clin Oncol; 2000 Jun; 18(12):2378-84. PubMed ID: 10856097
[TBL] [Abstract][Full Text] [Related]
16. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
Schilsky RL; Kindler HL
Expert Opin Investig Drugs; 2000 Jul; 9(7):1635-49. PubMed ID: 11060767
[TBL] [Abstract][Full Text] [Related]
17. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.
Rivera E; Valero V; Cristofanilli M; Frye DK; Booser DJ; Rosales MM; Hortobagyi GN
Cancer; 2002 May; 94(9):2321-6. PubMed ID: 12015755
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of weekly paclitaxel plus prolonged oral eniluracil/5-fluorouracil in patients with refractory malignancies.
Jones SF; Greco FA; Hainsworth JD; Patton JW; Barton JH; Willcutt NT; Baker MN; McGuirt PV; Levin J; Burris HA
Oncologist; 2002; 7(5):444-50. PubMed ID: 12401907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
